Why can't I see Refill pricing before I commit?

The pricing transparency problem shows up at the worst moment: a patient is in front of you ready to start semaglutide or tirzepatide, and you cannot tell them the cost because your platform does not show landed per-vial pricing. You either guess, quote a padded number to be safe, or tell the patient you will follow up — and follow-ups are where conversions go to die.

For owners, the same opacity makes margin planning a moving target. If the cost per vial is only knowable after a demo and can shift with volume tiers and software fees, building a predictable cash-pay program means working from estimates rather than numbers. The delay is not just minutes; it is the inability to make confident pricing decisions.

Refill negotiates medication pricing on aggregate volume across its 503A network and charges tiered software fees on transactions in its web app pricing tiers. Refill's homepage advertises pre-negotiated pricing and a meet-or-beat guarantee, but those numbers are not published per vial on refill.co as of June 2026 — you typically see them after a demo and onboarding. Software fees on top of med cost further complicate apples-to-apples comparison across concentrations and supply duration.

When you evaluate this model, the right questions are about timing and visibility: how long from demo to a usable catalog, whether per-vial rates show medication cost and software fee separately, and how rates change as your volume moves between tiers. If pricing never surfaces as pass-through on each cart line, the opacity repeats every time a new SKU or tier comes up.

The delay disappears when pricing is visible at the point of decision. Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout, with the facilitation fee disclosed at payment, so a clinician can quote a patient in the room and an owner can model margin from real numbers. There is no demo gate between you and the cost of the medication you are about to order.

Pass-through pricing is the structural difference: instead of an aggregate rate with a percentage software fee baked into the workflow, you see the 503A cost and the disclosed fee. The evaluation test is whether you can answer what does this vial cost without a sales conversation. When the catalog answers that question, the consult keeps moving and pricing stops being a bottleneck.